Filtered By:
Condition: Chronic Obstructive Pulmonary
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 686 results found since Jan 2013.
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines.
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Managing osteoporosis in COPD
Endocr Metab Immune Disord Drug Targets. 2023 Sep 13. doi: 10.2174/1871530323666230913105752. Online ahead of print.ABSTRACTChronic obstructive pulmonary disease (COPD) is a serious respiratory disease with high morbidity, disability and mortality worldwide. Every year, many people die from the disease or its comorbidities. Osteoporosis is a common complication of COPD, which can lead to increased fractures in COPD patients, aggravate the disease, and then bring great pain and burden to patients. The possible factors leading to osteoporosis in COPD patients include systemic inflammation, corticosteroid use, vitamin D defic...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - September 15, 2023 Category: Endocrinology Authors: Lilan Shen Juanqin Lv Jie Li Jing Zhou Xiaomin Wang Source Type: research
2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD
Chest. 2023 Sep 6:S0012-3692(23)05275-3. doi: 10.1016/j.chest.2023.08.014. Online ahead of print.ABSTRACTChronic obstructive pulmonary disease patient care must include confirming a diagnosis with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that airflow obstruction assessed by spirometry only partially reflects disease severity, a thorough clinical evaluation of the patient should include assessment of symptom burden and risk of exacerbations that permits the implementation of evidence-informed pharmacologic and nonpharmacologic interventions. This guideline provides recommendations...
Source: Chest - September 10, 2023 Category: Respiratory Medicine Authors: Jean Bourbeau Mohit Bhutani Paul Hernandez Shawn D Aaron Marie-France Beauchesne Sophie B Kermelly Anthony D'Urzo Avtar Lal Fran çois Maltais Jeffrey D Marciniuk Sunita Mulpuru Erika Penz Don D Sin Anne Van Dam Joshua Wald Brandie L Walker Darcy D Marcin Source Type: research
Pneumothorax, pneumomediastinum, and subcutaneous emphysema in hospitalized COVID-19 patients: incidence, clinical characteristics, and outcomes
CONCLUSION: Although the occurrence of PTX/PNM/SCE in hospitalized COVID-19 patients was rare, it was associated with worse outcomes. Corticosteroids may contribute to the pathogenesis of these complications; however, further studies are needed to investigate this relationship in more detail.PMID:37675598 | DOI:10.1080/17476348.2023.2254689
Source: Respiratory Care - September 7, 2023 Category: Respiratory Medicine Authors: Aleksandra Murawska Baptista Jorge Sinclair De Fr ías Trisha Singh Ananya Vasudhar Jacob Guzzino Waheed Khalili Aysun Tekin Vikas Bansal Rahul Kashyap William J Joyce Patricia A Lewis Devang Sanghavi Tatjana Gavrancic Pablo Moreno Franco Source Type: research
Duration and dosing of systemic corticosteroids for acute exacerbation of COPD, protocol for a systematic review with meta-analysis of randomized trials and cohort studies
DiscussionsTo our knowledge, this represents an updated and most comprehensive review of the literature comparing different duration and dosing regimen of corticosteroid treatments in AECOPD, as we will include both RCTs and observational studies without date or language restrictions. We aim to validate prior meta-analyses and study findings on the efficacy of short duration corticosteroid therapy over longer treatments and to inform future research directions in dosing regimens.
Source: PLoS One - August 31, 2023 Category: Biomedical Science Authors: Raymond Yin Source Type: research
Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
CONCLUSION: In a global study, comorbidity or multimorbidity is reported in most adults with severe asthma and is associated with poorer asthma-related outcomes.PMID:37640263 | DOI:10.1016/j.anai.2023.08.021
Source: Annals of Allergy, Asthma and Immunology - August 28, 2023 Category: Allergy & Immunology Authors: Ghislaine Scelo Carlos A Torres-Duque Jorge Maspero Trung N Tran Ruth Murray Neil Martin Andrew N Menzies-Gow Mark Hew Matthew J Peters Peter G Gibson George C Christoff Todor A Popov Andr éanne Côté Celine Bergeron Delbert Dorscheid J Mark FitzGerald Source Type: research
Inhaled Maintenance Therapy in the Follow-Up of COPD in Outpatient Respiratory Clinics. Factors Related to Inhaled Corticosteroid Use. EPOCONSUL 2021 Audit
CONCLUSIONS: Inhaled therapy in the follow-up of COPD does not always conform to the current guidelines. Few changes in inhaled therapy are made at follow-up visits. The use of ICS is common in COPD patients who meet low-risk criteria in their follow-up and triple therapy in high-risk COPD patients is used as an escalation strategy in patients with high clinical impact. However, a history of exacerbations and eosinophil count in peripheral blood were not factors predicting triple therapy.PMID:37563018 | DOI:10.1016/j.arbres.2023.07.015
Source: Archivos de Bronconeumologia - August 10, 2023 Category: Respiratory Medicine Authors: Myriam Calle Rubio Marc Miravitlles Jos é Luis López-Campos Bernardino Alc ázar Navarrete Juan Jos é Soler Cataluña Manuel E Fuentes Ferrer Juan Luis Rodr íguez Hermosa Source Type: research
